BDKRB2 and hereditary angioedema: Although specific therapy with Icatibant, a bradykinin B2 receptor antagonist currently approved for the treatment of HAE (15), has shown inconsistent results in the treatment of ACEi-induced angioedema, as evidenced by a recent meta-analysis of randomized controlled trials (20, 22).